Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(02): 71-75
DOI: 10.4103/0971-5851.89775
REVIEW ARTICLE

Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma

Mario Uccello
Departments of Senescence, Urological & Neurological Sciences, University of Catania, Catania, Italy
,
Giulia Malaguarnera
Departments of Senescence, Urological & Neurological Sciences, University of Catania, Catania, Italy
,
Elisa M Pelligra
Departments of Senescence, Urological & Neurological Sciences, University of Catania, Catania, Italy
,
Antonio Biondi
Department of Surgery, University of Catania, Catania, Italy
,
Francesco Basile
Department of Surgery, University of Catania, Catania, Italy
,
Massimo Motta
Departments of Senescence, Urological & Neurological Sciences, University of Catania, Catania, Italy
› Author Affiliations Source of Support Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

The residual liver function is a major clinical index in hepatocellular carcinoma (HCC) patients. As the liver plays a crucial role in lipid and lipoprotein metabolism, the significant impairment of the hepatic function occurring during chronic liver diseases, such as HCC, can influence plasma lipoprotein profiles. Although, lipoprotein(a) (Lp(a)) circulating concentrations are mostly determined by genetic factors, in the majority of reports they have shown a correlation with the hepatic status and a significant decrease in HCC and liver cirrhosis patients than among the controls. In such a way, Lp(a) may represent a new additional and useful marker for a more complete assessment and monitoring of the liver function in patients with HCC and liver cirrhosis. Further studies are needed in order to evaluate the clinical significance of Lp(a) in HCC.

Keywords

Chronic liver disease - hepatocellular carcinoma - liver function - lipoprotein(a)


Publication History

Article published online:
06 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Prescott LF, Forrest JA, Adjepon-Yamoah KK, Finlayson ND. Drug metabolism in liver disease. J Clin Pathol Suppl (R Coll Pathol) 1975;9:62-5.
  • 2 Bell AW. Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog Lipid Res 1979;18:117-64.
  • 3 Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:4.
  • 4 Wasan KM, Cassidy SM. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 1998;87:411-24.
  • 5 Shepherd J, Packard CJ. Lipid transport through the plasma: the metabolic basis of hyperlipidaemia. Baillieres Clin Endocrinol Metab 1987;1:495-514.
  • 6 Ginsberg HN, Taskinen MR. New insights into the regulation of lipoprotein metabolism: Studies in procaryocytes, eukaryocytes, rodents, pigs, and people. Curr Opin Lipidol 1997;8:127-30.
  • 7 Cooper AD. Hepatic lipoprotein metabolism: Recent molecular insights. Prog Liver Dis 1995;13:173-200.
  • 8 Dixon JL, Ginsberg HN. Hepatic synthesis of lipoproteins and apolipoproteins. Semin Liver Dis 1992;12:364-72.
  • 9 Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
  • 10 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
  • 11 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
  • 12 Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
  • 13 Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351:1773-7.
  • 14 Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008;28:160-74.
  • 15 Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:477-83.
  • 16 Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med 2001;92:301-5.
  • 17 Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med 2005;15:655-60.
  • 18 Ahaneku JE, Taylor GO, Olubuyide IO, Agbedana EO. Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocellular carcinoma. J Pak Med Assoc 1992;42:260-3.
  • 19 Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963;59:369-82.
  • 20 McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7.
  • 21 Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983;154:357-61.
  • 22 Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-10.
  • 23 Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
  • 24 Galvano F, Malaguarnera M, Vacante M, Motta M, Russo C, Malaguarnera G, et al. The physiopathology of lipoprotein (a). Front Biosci (Schol Ed) 2010;2:866-75.
  • 25 Guevara J Jr, Valentinova NV, Garcia O, Gotto AM, Yang CY, Legal S, et al. Interaction of apolipoprotein[a] with apolipoproteinB-100 Cys3734 region in lipoprotein[a] is confirmed immunochemically. J Protein Chem 1996;15:17-25.
  • 26 Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991;87:227-37.
  • 27 Levine DM, Sloan BJ, Donner JE, Lorenz JD, Heinzerling RH. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992;22:173-8.
  • 28 Kim CJ, Kim TH, Ryu WS, Ryoo UH. Influence of menopause on high density lipoprotein-cholesterol and lipids. J Korean Med Sci 2000;15:380-6.
  • 29 Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Restuccia N, Ruello P. Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr Med Res Opin 1996;13:479-85.
  • 30 Kung AW, Pang RW, Lauder I, Lam KS, Janus ED. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem 1995;41:226-31.
  • 31 Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem 1997;43:1891-5.
  • 32 Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: A meta-analysis of observational studies. Stroke 2007;38:1959-66.
  • 33 Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997;14:17-23.
  • 34 Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence. Interact Cardiovasc Thorac Surg 2009;9:467-70.
  • 35 Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28.
  • 36 Trégouët DA, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009;41:283-5.
  • 37 Lippi G, Franchini M, Salvagno GL, Guidi GC. Lipoprotein(a) and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev 2007;33:427-36.
  • 38 Manizate F, Hiotis SP, Labow D, Roayaie S, Schwartz M. Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology 2010;78:131-4.
  • 39 Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician 1999;59:2223-30.
  • 40 Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-76.
  • 41 Dohmen K. Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:1227-32.
  • 42 Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
  • 43 Ahmad J, Downey KK, Akoad M, Cacciarelli TV. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transpl 2007;13:1564-69.
  • 44 Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007;13:523-29.
  • 45 Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000.
  • 46 Jiang M, Liu F, Xiong WJ, Zhong L, Xu W, Xu F, et al. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol 2010;16:1397-401.
  • 47 Sheng QS, Lang R, He Q, Yang YJ, Zhao DF, Chen DZ. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int 2009;8:46-9.
  • 48 Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-43.
  • 49 Fan ST. Liver functional reserve estimation: State of the art and relevance for local treatments: The Eastern perspective. J Hepatobiliary Pancreat Sci 2010;17:380-4.
  • 50 Davis RA. Lipoprotein synthesis and secretion by cultured hepatocytes. Methods Enzymol 1986;129:272-83.
  • 51 Theriault A, Wang Q, Van Iderstine SC, Chen B, Franke AA, Adeli K. Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid. J Lipid Res 2000;41:1969-79.
  • 52 Samuels ME. Genetics of cholesterol and lipoprotein metabolism. Recent Pat Cardiovasc Drug Discov 2007;2:195-204.
  • 53 Beisiegel U. Lipoprotein metabolism. Eur Heart J 1998;19:A20-3.
  • 54 Illingworth DR. Lipoprotein metabolism. Am J Kidney Dis 1993;22:90-7.
  • 55 Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Siciliano R, Ruello P. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther 1995;17:721-8.
  • 56 White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 1993;34:509-17.
  • 57 White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994;269:28716-23.
  • 58 Samonakis DN, Koutroubakis IE, Sfiridaki A, Malliaraki N, Antoniou P, Romanos J, et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004;49:854-8.
  • 59 Irshad M. Serum lipoprotein (a) levels in liver diseases caused by hepatitis. Indian J Med Res 2004;120:542-5.
  • 60 Jiang J, Zhang X, Wu C, Qin X, Luo G, Deng H, et al. Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. Lipids Health Dis 2008;7:25.
  • 61 Malaguarnera M, Trovato G, Restuccia S, Giugno I, Franzé CM, Receputo G, et al. Treatment of nonresectable hepatocellular carcinoma: review of the literature and meta-analysis. Adv Ther 1994;11:303-19.
  • 62 Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983;71:1431-41.
  • 63 Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res 1977;18:331-8.
  • 64 Basili S, Andreozzi P, Vieri M, Maurelli M, Cara D, Cordova C, et al. Lipoprotein (a) serum levels in patients with hepatocarcinoma. Clin Chim Acta 1997;262:53-60.